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Background-—Urocortin 2 and urocortin 3 are endogenous peptides with an emerging role in cardiovascular pathophysiology. We
assessed their pharmacodynamic proﬁle and examined the role of the endothelium in mediating their vasomotor effects in vivo in
man.
Methods and Results-—Eighteen healthy male volunteers (234 years) were recruited into a series of double-blind, randomized
crossover studies using bilateral forearm venous occlusion plethysmography during intra-arterial urocortin 2 (3.6 to 120 pmol/
min), urocortin 3 (1.2 to 36 nmol/min), and substance P (2 to 8 pmol/min) in the presence or absence of inhibitors of
cyclooxygenase (aspirin), cytochrome P450 metabolites of arachidonic acid (ﬂuconazole), and nitric oxide synthase (L-NMMA).
Urocortins 2 and 3 evoked arterial vasodilatation (P<0.0001) without tachyphylaxis but with a slow onset and offset of action.
Inhibition of nitric oxide synthase with L-NMMA reduced vasodilatation to substance P and urocortin 2 (P≤0.001 for both) but had
little effect on urocortin 3 (P>0.05). Neither aspirin nor ﬂuconazole affected vasodilatation induced by any of the infusions (P>0.05
for all). In the presence of all 3 inhibitors, urocortin 2– and urocortin 3–induced vasodilatation was attenuated (P<0.001 for all) to a
greater extent than with L-NMMA alone (P≤0.005).
Conclusions-—Urocortins 2 and 3 cause potent and prolonged arterial vasodilatation without tachyphylaxis. These vasomotor
responses are at least partly mediated by endothelial nitric oxide and cytochrome P450 metabolites of arachidonic acid. The role of
urocortins 2 and 3 remains to be explored in the setting of human heart failure, but they have the potential to have major
therapeutic beneﬁts.
Clinical Trial Registration-—http://www.clinicaltrials.gov//. Unique identiﬁer: NCT01096706 and NCT01296607. ( J Am Heart
Assoc. 2013;2:e004267 doi: 10.1161/JAHA.112.004267)
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U rocortin peptides, especially urocortins 2 and 3, haveprominent cardiovascular roles and are expressed in the
heart. Although related to corticotrophin-releasing hormone
(CRH), they do not appear to have any role in the regulation of
the hypothalamic-pituitary-adrenal axis.1,2 The effects of CRH
and the urocortins are mediated via 2 G-protein-coupled
receptors: CRH-R1 and CRH-R2. Although CRH-R1 is predom-
inantly expressed in the brain and not in the heart, CRH-R2 is
expressed in the myocardium and vascular smooth muscle.2,3
It is found in human coronary artery microvascular endothelial
cells and has been detected in the endothelium of a variety of
peripheral vascular beds. Urocortin 1 activates both recep-
tors, whereas urocortins 2 and 3 are potent selective agonists
at CRH-R2 but have no effect on CRH-R1.4
The role of urocortins in cardiovascular physiology and
pathophysiology, particularly heart failure, has become increas-
ingly apparent. Intravenous urocortin 1 causes marked vaso-
dilatation in mice via CRH-R2.5,6 Furthermore, mice lacking
CRH-R2 receptors are hypertensive, suggesting a role for
urocortin in the maintenance of basal vascular tone.6 Systemic
administration of urocortin 2 in humans increases cardiac
output, heart rate, and left ventricular function while decreasing
systemic vascular resistance, and these effects may be
ampliﬁed in the setting of heart failure.7,8 Urocortin 3 has not
previously been administered to humans, but in an ovinemodel,
both urocortin 2 and urocortin 3 appeared to produce similar
cardiovascular effects.9,10 Although urocortin 2 and urocortin 3
each activate the same receptor, potential differences in their
cardiovascular therapeutic utility may arise from their differing
pharmacokinetic and pharmacodynamic proﬁles.1
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The cardiovascular responses of urocortins represent an
amalgamation of systemic actions. However, their direct in
vivo arterial vasomotor effects have never been examined in
humans. Moreover, the role of the endothelium in the
mediation of these responses is unknown. Therefore, our
study’s aims were to conduct the ﬁrst comparative clinical
assessment of local arterial vasomotor effects of urocortins 2
and 3 and to determine the role of the endothelium in the
mediation of these effects.
Methods
All studies were approved by the local research ethics
committee and carried out in accordance with the Declaration
of Helsinki. Written informed consent was obtained from all
participants prior to the study.
Study Participants
Eighteen healthy nonsmoking male volunteers were recruited
into the series of vascular studies. Participants had no
documented medical history, were taking no regular medica-
tions, and tested negative in a urinary toxicology screen (Nova
Test, One Step Diagnostic Rapid Test, CA) for recreational
drugs.
Vascular Studies
All studies were conducted using a double-blind, random-
ized, controlled crossover design. They were performed with
the patient lying supine in a quiet, temperature-controlled
room (22°C to 25°C). Volunteers fasted for 4 hours prior to
the study and refrained from alcohol and caffeine for
24 hours prior to the study. Venous cannulae (17G) were
inserted into large subcutaneous veins in the antecubital
fossae of both arms at the start of the study to facilitate
periodic venous sampling. In view of the theoretical risk of
alterations in body temperature11 and blood glucose
concentrations12 with the ﬁrst-in-human administration of
urocortin 3, tympanic temperature (Genius 2 Tympanic
Thermometer, Coviden, Boston, MA) and capillary blood
glucose (Advantage Accucheck blood glucometer, USA)
measurements were performed at baseline and after each
dose of urocortin 3. Heart rate and blood pressure were
monitored at regular intervals throughout the study with a
semiautomated oscillometric sphygmomanometer (Omron
705IT).
Subjects underwent brachial artery cannulation in the
nondominant forearm with a 27 standard wire-gauge steel
needle. Forearm blood ﬂow was measured in the infused and
noninfused forearms using bilateral venous occlusion pleth-
ysmography as described previously.13,14
Pharmacodynamic Study
Eight healthy volunteers attended on 4 occasions (protocol 1)
separated by at least 1 week (Figure 1A). After an initial
infusion of normal saline (0.9%) for 20 minutes, volunteers
received discontinuous (protocol 1a) or continuous (protocol
1b) incremental intra-arterial doses of urocortin 2 (3.6 to
120 pmol/min; Neurocrine Biosciences, Inc, San Diego, CA)
or urocortin 3 (1.2 to 36 nmol/min; GenScript, NJ)
interspersed with saline infusions between doses as
appropriate.
Mechanistic Study
An additional 10 healthy volunteers (protocol 2) attended on
each of 5 occasions to receive incremental intra-arterial doses
of urocortin 2 (3.6 to 36 pmol/min), urocortin 3 (1.2 to
12 nmol/min), and substance P (2 to 8 pmol/min; a control
endothelium-dependent vasodilator that evokes endothelial
tissue plasminogen activator release; Clinalfa Basic, Bachem
Distribution Services Gmbh, Germany) (Figure 1B). These
infusions were administered in the presence of (1) a placebo,
(2) oral aspirin 600 mg (cyclo-oxygenase inhibition), (3) a
“nitric oxide clamp” (nitric oxide synthase inhibition; see
below), (4) intra-arterial ﬂuconazole (1.2 lmol/min; inhibition
of cytochrome P450 metabolites of arachidonic acid), and
(5) a combination of oral aspirin, intra-arterial ﬂuconazole, and
the nitric oxide (NO) clamp.
The nitric oxide clamp was used to determine the
contribution of nitric oxide to urocortin-induced vasodilata-
tion. Following baseline saline infusion, the nitric oxide
synthase inhibitor L-N(G)-monomethyl arginine citrate
(L-NMMA; 8 lmol/min; Clinalfa Basic, Bachem Distribution
Services Gmbh, Germany) was infused intra-arterially. To
compensate for L-NMMA-induced basal vasoconstriction,
forearm blood ﬂow was returned to baseline using a titrated
dose of the exogenous nitric oxide donor sodium nitroprus-
side (SNP; 90 to 1200 ng/min; Hospira Inc, Lake Forest, IL).
Once baseline blood ﬂow had been restored, this dose of SNP
was coinfused with L-NMMA and continued throughout the
study. This arrangement allows a constant “clamped” delivery
of exogenous nitric oxide while endogenous nitric oxide
synthase activity is abolished.
The order of urocortin 2, urocortin 3, and substance P
infusions was randomized between subjects but kept con-
stant for all visits of each individual subject. The order of
infusion of inhibitors was also randomized in a double-blind
manner.
Venous Sampling
Blood sampling was carried out at baseline for the assess-
ment of full blood count, liver and renal function tests,
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Figure 1. Schematic representation of study protocols. A, Protocol 1—incremental intra-arterial doses of urocortin 2 (Ucn 2; 3.6 to 120 pmol/
min) and urocortin 3 (Ucn 3; 1.2 to 36 nmol/min) in the presence (protocol 1a) and absence (protocol 1b) of saline washout. B, Protocol 2—
incremental intra-arterial infusions of Ucn 2 (3.6 to 36 pmol/min), Ucn 3 (1.2 to 12 nmol/min), and substance P (sub P; 2 to 8 pmol/min) in the
presence of (1) saline placebo, (2) oral aspirin, (3) “nitric oxide” clamp, (4) intra-arterial ﬂuconazole, and (5) a combination of oral aspirin,
ﬂuconazole, and nitric oxide clamp. L-NMMA indicates L-N(G)-monomethyl arginine citrate.
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cholesterol, and blood glucose levels. Analysis was performed
by the local clinical biochemistry and hematology reference
laboratories.
Data Analysis and Statistics
Forearm blood ﬂow data were analyzed as described previ-
ously.13 A normal distribution of the data was demonstrated
using the D’Agostino & Pearson omnibus normality test.
All variables are reported as meanSEM using repeated-
measures analysis of variance (ANOVA) with post hoc
Bonferroni corrections and a 2-tailed Student t test as
appropriate (Graph-Pad Prism, GraphPad Software, San Diego,
CA). Signiﬁcance was taken as 2-sided P<0.05.
Results
Study Participants
All volunteers were young healthy men (234 years). Both
urocortin 2 and urocortin 3 produced marked localized
ﬂushing in the infused arm along with facial ﬂushing at the
highest doses. Volunteers also experienced heightened
awareness of their heartbeat during and immediately after
the highest dose of urocortin 3 (36 nmol/min). All symptoms
were self-limiting, well tolerated, and short-lived. Substance P
also induced localized ﬂushing of the infused forearm, which
was self-limiting. There were no clinically signiﬁcant changes
in the standard hematological and biochemical analytes
including full blood count, blood glucose, cholesterol, and
renal and hepatic function throughout the study (data on ﬁle).
Capillary blood glucose and body temperature (tympanic)
remained unchanged during all doses of urocortin 3 (data on
ﬁle).
Systolic blood pressure and noninfused forearm blood ﬂow
remained unchanged at all doses with all 3 peptides across
both protocols. However, at the highest infused dose of
urocortin 3 (36 nmol/min), there was a sinus tachycardia
(+222 beats/min; ANOVA, P<0.0001) with an associated
drop in diastolic blood pressure (8.50.8 mm Hg; ANOVA
P=0.004; Figure 2) that was not seen with either substance P
or urocortin 2 infusions.
Pharmacodynamic Effects of Urocortins 2 and 3
Both urocortin 2 and urocortin 3 evoked dose-dependent
arterial vasodilatation in the infused arm (2-way ANOVA,
P<0.0001) (Figure 3).
Maximal vasodilatation with urocortin 2 was apparent
10 minutes after cessation of the 120 pmol/min infusion
(paired Student t test, Ucn 2 120 pmol/min versus +10-
minute washout; P=0.04), and thereafter the blood ﬂow
gradually returned toward baseline. This was in contrast to the
effect seen with urocortin 3, for which the maximum
vasodilatory response was immediate (Figure 4A). The offset
of vasodilatation was prolonged with both peptides, although
urocortin 2 took longer than urocortin 3 to return to baseline
(Figure 4A).
The vasodilator effects of both peptides appeared to be
reproducible within a day, with no evidence of tachyphylaxis
(2-way ANOVA, P>0.05 for all; Figure 4B).
Endogenous Fibrinolytic Factors
Preliminary data showed no effect of urocortin 2 or urocortin
3 on endothelial release of tissue plasminogen activator and
plasminogen activator inhibitor-1 (data on ﬁle).
Mechanism of Vasodilatation
Baseline forearm arterial blood ﬂow was unaffected by oral
aspirin or intra-arterial ﬂuconazole, and the coinfusion of SNP
restored baseline blood ﬂow during L-NMMA administration
(2-way ANOVA, P>0.05 for all). Inhibition of nitric oxide
synthase reduced arterial vasodilatation to substance P and
urocortin 2 (2-way ANOVA, P≤0.001 for both) but had no
Figure 2. Hemodynamic responses to intra-arterial infusion of
urocortin 2 (Ucn 2; 3.6 to 120 pmol/min) and urocortin 3 (Ucn 3; 1.2
to 36 nmol/min). At a dose of 36 nmol/min, Ucn 3 evoked transient
tachycardia associated with a drop in diastolic blood pressure. Open
symbols, Ucn 2; closed symbols, Ucn 3; circle, heart rate; square,
systolic blood pressure (BP); triangle, diastolic BP; ***P<0.0001;
**P=0.004; dose 1=3.6 pmol/min Ucn 2 or 1.2 nmol/min Ucn 3;
dose 2=12 pmol/min Ucn 2 or 3.6 nmol/min Ucn 3; dose 3=36
pmol/min Ucn 2 or 12 nmol/min Ucn 3; dose 4=120 pmol/min
Ucn 2 or 36 nmol/min Ucn 3; bpm indicates beats per minute.
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apparent effect on urocortin 3–induced vasodilatation (2-way
ANOVA, P=0.36). Neither inhibition of cyclo-oxygenase with
aspirin nor cytochrome P450 metabolites of arachidonic acid
with ﬂuconazole affected the vasodilatation induced by the
urocortins or substance P (2-way ANOVA, P>0.05 for all; data
on ﬁle). In the presence of all 3 inhibitors, substance P–,
urocortin 2–, and urocortin 3–induced vasodilatation was
further attenuated (2-way ANOVA, P<0.001 for all) but
not completely abolished. Combined inhibition of cyclo-
oxygenase, nitric oxide synthase, and cytochrome P450
metabolites of arachidonic acid produced a greater reduction
in vasodilatation than the nitric oxide clamp alone (2-way
ANOVA, P≤0.005 for urocortins 2 and 3; Figure 5).
Discussion
This study represents the ﬁrst administration in humans of
urocortin 3 and demonstrates that both urocortin 2 and
urocortin 3 directly evoke potent and prolonged arterial
vasodilatation that is, at least in part, mediated by the
endothelium. These ﬁndings are of direct relevance not only
to our understanding of human cardiovascular physiology but
also inform the development of therapies targeting the
urocortin system for the treatment of conditions such as
heart failure.
The forearm arterial vasodilator effects of urocortin 2 and
urocortin 3 are consistent with data from in vitro3,15–18 and
preclinical19,20 animal studies. However, in contrast with
existing preclinical data, we observed a more marked
difference in potency between the 2 peptides. Although
preclinical studies have suggested urocortin 2 is 10-fold more
potent,21,22 Wiley et al3 showed equipotency of urocortins 2
and 3 in isolated human internal mammary arterial segments.
In contrast, here we observed that a 300-fold-higher dose of
urocortin 3 was required to evoke comparable vasomotor
effects in human forearm arterial circulation. This discrepancy
underlines the importance of a direct head-to-head assess-
ment in vivo in humans, without which the extrapolation of
preclinical data may be deceptive.
Urocortins 2 and 3 are speciﬁc agonists at the
G-protein-coupled CRH-R2 receptors, mediating their effects
through a cascade of intracellular signaling pathways includ-
ing adenyl cyclase, cyclic adenosine monophosphate,23,24 and
mitogen-activated protein kinases.25 Other well-characterized
G-protein-coupled receptor agonists such as bradykinin,26,27
substance P,28 and protease activated receptor type 1
activating peptide29,30 evoke vasodilatation with rapid onset
and offset in human forearm arterial circulation. Unlike these
agonists, the maximal vasodilator effect evoked by urocortin 2
in this study was apparent 10 minutes following completion
of the highest dose (protocol 1a). In addition to a late maximal
response with urocortin 2, we also observed a prolonged
offset. Even 100 minutes post–urocortin 2 administration,
infused forearm blood ﬂow remained elevated. Although
not as lengthy as the effect evoked by urocortin 2, urocortin
3–evoked vasodilatation was also prolonged and took 1 hour
for blood ﬂow to return to baseline after discontinuation of the
infusion. This prolonged offset of effect is unusual for
G-protein-coupled receptor agonists, although a similar time
course has been observed in response to apelin31 and
vasopressin,32 and is thought to be the result of prolonged
receptor occupancy. In vitro studies by Hoare et al33 have
demonstrated differing afﬁnities of urocortin 2 and urocortin 3
to the CRF-R2 receptor determined by the afﬁnity of the
Figure 3. Forearm arterial blood ﬂow responses to increasing doses of urocortin 2 (Ucn 2) and urocortin 3 (Ucn 3). Circle, infused forearm blood
ﬂow; square, noninfused forearm blood ﬂow. P<0.0001 at all doses.
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extracellular domains of the CRF receptors to these agonists.
It remains to be established whether urocortin 2 induces
receptor transformation, thereby promoting prolonged binding
to CRH-R2 and a delayed maximal response. However, when
assessed in isolation, it is clear that the direct vasomotor
effects of urocortin 2 and urocortin 3 are more prolonged than
previously reported.
The vasodilator effects of both peptides showed good
within-day reproducibility without evidence of tachyphylaxis.
These are important properties, especially for potential
applications in extended or chronic therapies in which
predictable and reproducible pharmacologic and hemodynam-
ic effects are needed.
Several mechanisms have been proposed to explain the
mechanistic pathways of urocortin-mediated vasorelaxation.
Studies to date have suggested that the mechanism involved
may depend on the species or vascular bed in question. In
rats, both endothelium-dependent17,34 and -independent
components were implicated.35 Grossini et al36 demonstrated
that urocortin 2–mediated vasorelaxation in the coronary
arteries of anaesthetized pigs was mediated by nitric oxide.
However, urocortin-mediated vasodilatation appeared to be
independent of endothelial integrity in isolated human coro-
nary and internal mammary artery segments.3,16 In the
current study, the NO clamp appeared to cause modest
inhibition of urocortin 2–mediated vasodilatation and
Figure 4. Pharmacodynamics of urocortin 2 (Ucn 2) and urocortin 3 (Ucn 3). A, Onset and offset of vasodilatory effect of Ucn 2 (left) and Ucn 3
(right) after infusion of highest dose. B, Within-day reproducibility of Ucn 2 (left) and Ucn 3 (right); P=nonsigniﬁcant, ﬁrst dose response vs second
dose response; Ucn 2 and Ucn 3. Closed circle: ﬁrst dose response; open circle, second dose response.
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appeared to be marginally more pronounced with urocortin 2
compared with urocortin 3. Inhibition of cytochrome P450
metabolites of arachidonic acid with ﬂuconazole alone did not
have an appreciable effect on urocortin-mediated vasodilata-
tion, but its addition enhanced the inhibitory effect of the NO
clamp. This suggests that endogenous nitric oxide and
cytochrome P450 metabolites of arachidonic acid may have
a close interrelationship and can compensate for one another
to maintain vascular tone. A similar effect has previously been
described for endothelium-derived hyperpolarizing factor
(EDHF), whereby its relative importance increases in the face
of impaired NO bioavailability under conditions of oxidative
stress. Although urocortin 2– and urocortin 3–mediated
vasodilatation was inhibited by the combination of all 3
inhibitors, it was not abolished, and a substantial degree of
vasomotor activity remained. We cannot exclude a contribu-
tion from other endothelial pathways such as residual
“ﬂuconazole-insensitive” EDHF, although the results do sug-
gest a substantial contribution from direct smooth muscle
activation. Although the role of the endothelium is substantial,
a large contribution from endothelium-independent vasodila-
tor mechanisms may be seen as an advantage in the potential
therapeutic applications of CRH-R2 agonism. Arguably, this
would allow a more predictable response from the manipu-
lation of urocortin (2 or 3) as a therapy for cardiovascular
conditions, the vast majority of which would be expected to
be associated with impaired endothelial homeostatic mech-
anisms but preserved smooth muscle activity.
This study was designed to assess locally active, subsys-
temic doses of urocortins 2 and 3 in forearm arterial
vasculature. Indeed, the forearm venous occlusion plethys-
mography model allows these local effects to be studied at
doses 10- to 100-fold lower than that usually expected or
required to elicit a systemic response. It would appear,
however, that there was a degree of systemic overspill
associated with the top dose of urocortin 3 tested. The
observed decrease in diastolic blood pressure and increase in
heart rate observed during and after the infusion of the top
dose of urocortin 3 is notable, particularly as it occurred in the
absence of any change in blood ﬂow in the contralateral
noninfused forearm. Usually, in the case of systemic overspill,
a corresponding change in the “control” noninfused arm
would be observed,28 but this was not the case with the
infusion of the dose of urocortin 3. We therefore hypothesize
that the hypotensive effect observed reﬂects vasodilatation in
another, more sensitive vascular bed, such as splanchnic
circulation, with consequent reﬂex tachycardia. Absence of a
similar hemodynamic response to the highest dose of
urocortin 2 may be the result of lower subsystemic doses of
the less potent peptide urocortin subtype or, conceivably, a
differential in the relative sensitivity of splanchnic and forearm
arterial circulation to urocortin 2. However, systemic doses up
to 100 lg of urocortin 2 have been shown to increase heart
rate and decrease diastolic blood pressures in healthy adults.7
Study Limitations
The size of our study population was relatively small.
However, we have previously described the inﬂuence of a
range of factors on blood ﬂow in forearm vasculature using
sample sizes of ≤12 subjects28–31,37–39 As with most other
physiological studies, we have not performed multiple testing
correction for the data obtained.
We studied the changes in forearm blood ﬂow during brief
local intrabrachial infusions of urocortins 2 and 3. The
apparent differences between urocortin 2 and urocortin 3
observed in our study may reﬂect, in part, differences
between the 2 peptides in the tissue exposure achieved.
Figure 5. Vasomotor effects of inhibition of endothelial nitric oxide synthase, cycloxygenase, and cytochrome P450 metabolites of arachidonic
acid on urocortin 2–, urocortin 3–, and substance P–mediated vasodilatation. Open circle, placebo; closed circle, nitric oxide clamp; closed
triangle, combined aspirin (600 mg), nitric oxide clamp, and ﬂuconazole (1.2 lmol/min).
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We do not as yet know the effects of prolonged infusions
of these peptides. Moreover, the effects of urocortins 2 and 3
in patients with heart failure remain to be explored. Although
there is good concordance between the vasomotor responses
observed in the forearm resistance vessels and other vascular
beds,40 further studies will be required to explore their
systemic effects in health and disease in humans.
Conclusions
We have demonstrated that urocortin 2 and urocortin 3 evoke
potent prolonged arterial vasodilatation and that their effects
are at least partly dependent on endothelial nitric oxide and
cytochrome P450 metabolites of arachidonic acid. These data
provide important insights into human cardiovascular physi-
ology, and they will inform the development of further
therapies directed toward the urocortin pathway. The in vivo
role of this endogenous peptide system in patients with heart
failure and the role of CRH-R2 in human health and disease
remain to be explored.
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